Generic placeholder image

Current Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 0929-8673
ISSN (Online): 1875-533X

Editorial

Costimulation Blockade Resistant Rejection

Author(s): Dimitrios Moris*

Volume 29, Issue 21, 2022

Published on: 18 January, 2022

Page: [3663 - 3666] Pages: 4

DOI: 10.2174/0929867328666211213153859

conference banner
[1]
Larsen, C.P.; Elwood, E.T.; Alexander, D.Z.; Ritchie, S.C.; Hendrix, R.; Tucker-Burden, C.; Cho, H.R.; Aruffo, A.; Hollenbaugh, D.; Linsley, P.S.; Winn, K.J.; Pearson, T.C. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature, 1996, 381(6581), 434-438.
[http://dx.doi.org/10.1038/381434a0] [PMID: 8632801]
[2]
Judge, T.A.; Tang, A.; Spain, L.M.; Deans-Gratiot, J.; Sayegh, M.H.; Turka, L.A. The in vivo mechanism of action of CTLA4Ig. J. Immunol., 1996, 156(6), 2294-2299.
[PMID: 8690920]
[3]
Vincenti, F.; Rostaing, L.; Grinyo, J.; Rice, K.; Steinberg, S.; Gaite, L.; Moal, M.C.; Mondragon-Ramirez, G.A.; Kothari, J.; Polinsky, M.S.; Meier-Kriesche, H.U.; Munier, S.; Larsen, C.P. Belatacept and long-term outcomes in kidney transplantation. N. Engl. J. Med., 2016, 374(4), 333-343.
[http://dx.doi.org/10.1056/NEJMoa1506027] [PMID: 26816011]
[4]
Wen, X.; Casey, M.J.; Santos, A.H.; Hartzema, A.; Womer, K.L. Comparison of utilization and clinical outcomes for Belatacept- and Tacrolimus-based immunosuppression in renal transplant recipients. Am. J. Transplant., 2016, 16(11), 3202-3211.
[http://dx.doi.org/10.1111/ajt.13853] [PMID: 27137884]
[5]
Vincenti, F.; Larsen, C.P.; Alberu, J.; Bresnahan, B.; Garcia, V.D.; Kothari, J.; Lang, P.; Urrea, E.M.; Massari, P.; Mondragon-Ramirez, G.; Reyes-Acevedo, R.; Rice, K.; Rostaing, L.; Steinberg, S.; Xing, J.; Agarwal, M.; Harler, M.B.; Charpentier, B. Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients. Am. J. Transplant., 2012, 12(1), 210-217.
[http://dx.doi.org/10.1111/j.1600-6143.2011.03785.x] [PMID: 21992533]
[6]
Larsen, C.P.; Pearson, T.C.; Adams, A.B.; Tso, P.; Shirasugi, N.; Strobert, E.; Anderson, D.; Cowan, S.; Price, K.; Naemura, J.; Emswiler, J.; Greene, J.; Turk, L.A.; Bajorath, J.; Townsend, R.; Hagerty, D.; Linsley, P.S.; Peach, R.J. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am. J. Transplant., 2005, 5(3), 443-453.
[http://dx.doi.org/10.1111/j.1600-6143.2005.00749.x] [PMID: 15707398]
[7]
Mou, D.; Espinosa, J.; Lo, D.J.; Kirk, A.D. CD28 negative T cells: is their loss our gain? Am. J. Transplant., 2014, 14(11), 2460-2466.
[http://dx.doi.org/10.1111/ajt.12937] [PMID: 25323029]
[8]
Shaw, B.I.; Espinosa, J.R.; Stempora, L.; Miller, A.; Adams, B.; Kirk, A.D. Functional characteristics and phenotypic plasticity of CD57+PD1- CD4 T cells and their relationship with transplant immunosuppression. J. Immunol., 2021, 206(7), 1668-1676.
[http://dx.doi.org/10.4049/jimmunol.2000736] [PMID: 33597150]
[9]
Espinosa, J.; Herr, F.; Tharp, G.; Bosinger, S.; Song, M.; Farris, A.B., III; George, R.; Cheeseman, J.; Stempora, L.; Townsend, R.; Durrbach, A.; Kirk, A.D. CD57(+) CD4 T cells underlie Belatacept-resistant allograft rejection. Am. J. Transplant., 2016, 16(4), 1102-1112.
[http://dx.doi.org/10.1111/ajt.13613] [PMID: 26603381]
[10]
Xu, H.; Bendersky, V.A.; Brennan, T.V.; Espinosa, J.R.; Kirk, A.D. IL-7 receptor heterogeneity as a mechanism for repertoire change during postdepletional homeostatic proliferation and its relation to costimulation blockade-resistant rejection. Am. J. Transplant., 2018, 18(3), 720-730.
[http://dx.doi.org/10.1111/ajt.14589] [PMID: 29136317]
[11]
Espinosa, J.A.B.; Kearns, J.; Shaw, F.; Osborne, R.; Woody, T.; Ellis, M.; Cheeseman, J.; Kirk, A. Activation requirements of costimulation blockade-resistant CD4 T cells. Am. J. Transplant., 2018, 18(S4), 282.
[12]
Sun, H.; Hartigan, C.R.; Chen, C.W.; Sun, Y.; Tariq, M.; Robertson, J.M.; Krummey, S.M.; Mehta, A.K.; Ford, M.L. TIGIT regulates apoptosis of risky memory T cell subsets implicated in belatacept-resistant rejection. Am. J. Transplant., 2021, 21(10), 3256-3267.
[http://dx.doi.org/10.1111/ajt.16571] [PMID: 33756063]
[13]
Espinosa, J.R.; Samy, K.P.; Kirk, A.D. Memory T cells in organ transplantation: progress and challenges. Nat. Rev. Nephrol., 2016, 12(6), 339-347.
[http://dx.doi.org/10.1038/nrneph.2016.9] [PMID: 26923209]
[14]
Page, A.J.; Ford, M.L.; Kirk, A.D. Memory T-cell-specific therapeutics in organ transplantation. Curr. Opin. Organ Transplant., 2009, 14(6), 643-649.
[http://dx.doi.org/10.1097/MOT.0b013e328332bd4a] [PMID: 19779342]
[15]
Linsley, P.S.; Ledbetter, J.A. The role of the CD28 receptor during T cell responses to antigen. Annu. Rev. Immunol., 1993, 11, 191-212.
[http://dx.doi.org/10.1146/annurev.iy.11.040193.001203] [PMID: 8386518]
[16]
Larsen, C.P.; Knechtle, S.J.; Adams, A.; Pearson, T.; Kirk, A.D. A new look at blockade of T-cell costimulation: a therapeutic strategy for long-term maintenance immunosuppression. Am. J. Transplant., 2006, 6(5 Pt 1), 876-883.
[http://dx.doi.org/10.1111/j.1600-6143.2006.01259.x] [PMID: 16611323]
[17]
Neller, M.A.; Ladell, K.; McLaren, J.E.; Matthews, K.K.; Gostick, E.; Pentier, J.M.; Dolton, G.; Schauenburg, A.J.; Koning, D.; Fontaine Costa, A.I.; Watkins, T.S.; Venturi, V.; Smith, C.; Khanna, R.; Miners, K.; Clement, M.; Wooldridge, L.; Cole, D.K.; van Baarle, D.; Sewell, A.K.; Burrows, S.R.; Price, D.A.; Miles, J.J. Naive CD8+ T-cell precursors display structured TCR repertoires and composite antigen-driven selection dynamics. Immunol. Cell Biol., 2015, 93(7), 625-633.
[http://dx.doi.org/10.1038/icb.2015.17] [PMID: 25801351]
[18]
Badell, I.R.; Kitchens, W.H.; Wagener, M.E.; Lukacher, A.E.; Larsen, C.P.; Ford, M.L. Pathogen stimulation history impacts donor-specific CD8(+) T cell susceptibility to Costimulation/Integrin blockade-based therapy. Am. J. Transplant., 2015, 15(12), 3081-3094.
[http://dx.doi.org/10.1111/ajt.13399] [PMID: 26228897]
[19]
Espinosa, J.R.; Mou, D.; Adams, B.W.; DiBernardo, L.R.; MacDonald, A.L.; McRae, M.; Miller, A.N.; Song, M.; Stempora, L.L.; Wang, J.; Iwakoshi, N.N.; Kirk, A.D.T. Cell repertoire maturation induced by persistent and latent viral infection is insufficient to induce costimulation blockade resistant organ allograft rejection in mice. Front. Immunol., 2018, 9, 1371.
[http://dx.doi.org/10.3389/fimmu.2018.01371] [PMID: 29963060]
[20]
Mou, D.; Espinosa, J.E.; Stempora, L.; Iwakoshi, N.N.; Kirk, A.D. Viral-induced CD28 loss evokes costimulation independent alloimmunity. J. Surg. Res., 2015, 196(2), 241-246.
[http://dx.doi.org/10.1016/j.jss.2015.02.033] [PMID: 25801976]
[21]
Adams, A.B.; Williams, M.A.; Jones, T.R.; Shirasugi, N.; Durham, M.M.; Kaech, S.M.; Wherry, E.J.; Onami, T.; Lanier, J.G.; Kokko, K.E.; Pearson, T.C.; Ahmed, R.; Larsen, C.P. Heterologous immunity provides a potent barrier to transplantation tolerance. J. Clin. Invest., 2003, 111(12), 1887-1895.
[http://dx.doi.org/10.1172/JCI200317477] [PMID: 12813024]
[22]
Ettenger, R.; Chin, H.; Kesler, K.; Bridges, N.; Grimm, P.; Reed, E.F.; Sarwal, M.; Sibley, R.; Tsai, E.; Warshaw, B.; Kirk, A.D. Relationship among viremia/viral infection, alloimmunity, and nutritional parameters in the first year after pediatric kidney transplantation. Am. J. Transplant., 2017, 17(6), 1549-1562.
[http://dx.doi.org/10.1111/ajt.14169] [PMID: 27989013]
[23]
Jameson, S.C.; Masopust, D. Diversity in T cell memory: an embarrassment of riches. Immunity, 2009, 31(6), 859-871.
[http://dx.doi.org/10.1016/j.immuni.2009.11.007] [PMID: 20064446]
[24]
Zhan, Y.; Carrington, E.M.; Zhang, Y.; Heinzel, S.; Lew, A.M. Life and death of activated T cells: how are they different from Naïve T cells? Front. Immunol., 2017, 8, 1809.
[http://dx.doi.org/10.3389/fimmu.2017.01809] [PMID: 29326701]
[25]
hKumar, B.V.; Connors, T.J.; Farber, D.L.; Human, T. human t cell development, localization, and function throughout life. Immunity, 2018, 48(2), 202-213.
[http://dx.doi.org/10.1016/j.immuni.2018.01.007] [PMID: 29466753]
[26]
Klenerman, P. The (gradual) rise of memory inflation. Immunol. Rev., 2018, 283(1), 99-112.
[http://dx.doi.org/10.1111/imr.12653] [PMID: 29664577]
[27]
Vincenti, F.; Charpentier, B.; Vanrenterghem, Y.; Rostaing, L.; Bresnahan, B.; Darji, P.; Massari, P.; Mondragon-Ramirez, G.A.; Agarwal, M.; Di Russo, G.; Lin, C.S.; Garg, P.; Larsen, C.P. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am. J. Transplant., 2010, 10(3), 535-546.
[http://dx.doi.org/10.1111/j.1600-6143.2009.03005.x] [PMID: 20415897]
[28]
Schmitz, R.; Fitch, Z.W.; Xu, H.; Ghali, A.; Mehta, A.K.; Guasch, A.; Kirk, A.D. Kidney transplantation using alemtuzumab, belatacept, and sirolimus: five-year follow-up. Am. J. Transplant., 2020, 20(12), 3609-3619.
[http://dx.doi.org/10.1111/ajt.16121] [PMID: 32515087]
[29]
Kirk, A.D.; Adams, A.B.; Durrbach, A.; Ford, M.L.; Hildeman, D.A.; Larsen, C.P.; Vincenti, F.; Wojciechowski, D.; Woodle, E.S. Optimization of de novo belatacept-based immunosuppression administered to renal transplant recipients. Am. J. Transplant., 2021, 21(5), 1691-1698.
[http://dx.doi.org/10.1111/ajt.16386] [PMID: 33128812]
[30]
Adams, A.B.; Goldstein, J.; Garrett, C.; Zhang, R.; Patzer, R.E.; Newell, K.A.; Turgeon, N.A.; Chami, A.S.; Guasch, A.; Kirk, A.D.; Pastan, S.O.; Pearson, T.C.; Larsen, C.P. Belatacept combined with transient Calcineurin inhibitor therapy prevents rejection and promotes improved long-term renal allograft function. Am. J. Transplant., 2017, 17(11), 2922-2936.
[http://dx.doi.org/10.1111/ajt.14353] [PMID: 28544101]

© 2024 Bentham Science Publishers | Privacy Policy